PapersFlow Research Brief
Autoimmune and Inflammatory Disorders
Research Guide
What is Autoimmune and Inflammatory Disorders?
Autoimmune and inflammatory disorders in this context refer to a cluster of conditions associating neutrophilic dermatoses such as Pyoderma Gangrenosum and Sweet's Syndrome with inflammatory bowel diseases, encompassing clinical features, treatment strategies, pathophysiology, and links to autoinflammatory skin disorders.
This field includes 40,692 works focused on neutrophilic dermatoses like Pyoderma Gangrenosum and Sweet's Syndrome linked to inflammatory bowel diseases. Key areas cover clinical features, pathophysiology, and treatments including biologics such as infliximab and vedolizumab. Growth rate over the past 5 years is not available from the data.
Topic Hierarchy
Research Sub-Topics
Pyoderma Gangrenosum Pathophysiology
Researchers elucidate immune dysregulation, neutrophil hyperactivity, and cytokine profiles in pyoderma gangrenosum lesions. Genetic and proteomic studies identify disease mechanisms.
Sweet's Syndrome Clinical Features
This sub-topic characterizes dermatologic, systemic, and histopathologic presentations of Sweet's syndrome, including malignancy-associated variants. Diagnostic criteria refinements are proposed.
Neutrophilic Dermatoses and IBD Association
Studies quantify extraintestinal manifestations linking pyoderma gangrenosum and Sweet's syndrome to Crohn's disease and ulcerative colitis. Shared genetic and inflammatory pathways are explored.
Biologic Therapies for Neutrophilic Dermatoses
Clinical trials evaluate anti-TNF, IL-1 inhibitors, and anti-IL17 agents for refractory pyoderma gangrenosum and Sweet's syndrome. Response rates and safety profiles are assessed.
Autoinflammatory Skin Disorders Classification
Researchers propose taxonomic frameworks grouping neutrophilic dermatoses with autoinflammatory syndromes based on genetics, cytokines, and histopathology. Differential features from autoimmune disorders are delineated.
Why It Matters
These disorders impact patients through severe skin and gastrointestinal manifestations, with treatments like infliximab enabling fistula closure in 68% of Crohn's disease patients at week 10 compared to 29% on placebo, as shown in "Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease" by Present et al. (1999). Maintenance infliximab every 8 weeks sustained response in fistulizing Crohn's over 54 weeks, per "Infliximab Maintenance Therapy for Fistulizing Crohn's Disease" by Sands et al. (2004). Vedolizumab induced remission in Crohn's patients, with 14.5% achieving clinical remission at week 6 versus 6.8% on placebo, according to "Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease" by Sandborn et al. (2013). Cyclophosphamide and glucocorticoids improved outcomes in 158 Wegener granulomatosis patients, though morbidity persists, from "Wegener Granulomatosis: An Analysis of 158 Patients" by Hoffman et al. (1992). These therapies target specific pathways in gastroenterology and dermatology, reducing hospitalization and surgery needs.
Reading Guide
Where to Start
"A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY" by Harvey and Bradshaw (1980) is the beginner start because it offers a straightforward clinical tool for assessing Crohn's activity, central to understanding inflammatory bowel disease associations with skin disorders.
Key Papers Explained
Bradley et al. (1982) in "Measurement of Cutaneous Inflammation: Estimation of Neutrophil Content with an Enzyme Marker" established neutrophil quantification, foundational for neutrophilic dermatoses. Harvey and Bradshaw (1980) in "A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY" provided disease activity metrics linking to bowel inflammation. Present et al. (1999) and Sands et al. (2004) in "Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease" and "Infliximab Maintenance Therapy for Fistulizing Crohn's Disease" built therapeutic evidence on induction and maintenance. Sandborn et al. (2013) in "Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease" extended to gut-selective biologics. Hoffman et al. (1992) in "Wegener Granulomatosis: An Analysis of 158 Patients" connected systemic vasculitis outcomes.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints are unavailable, so frontiers remain tied to top papers' unresolved issues like optimizing biologic durability and reducing morbidity in vasculitis-associated disorders.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Measurement of Cutaneous Inflammation: Estimation of Neutrophi... | 1982 | Journal of Investigati... | 3.6K | ✓ |
| 2 | A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY | 1980 | The Lancet | 2.9K | ✕ |
| 3 | Wegener Granulomatosis: An Analysis of 158 Patients | 1992 | Annals of Internal Med... | 2.9K | ✕ |
| 4 | Infliximab for the Treatment of Fistulas in Patients with Croh... | 1999 | New England Journal of... | 2.7K | ✓ |
| 5 | Vedolizumab as Induction and Maintenance Therapy for Crohn's D... | 2013 | New England Journal of... | 2.6K | ✓ |
| 6 | HISTOPATHOLOGY OF THE SKIN | 1950 | Plastic & Reconstructi... | 2.6K | ✓ |
| 7 | Infliximab Maintenance Therapy for Fistulizing Crohn's Disease | 2004 | New England Journal of... | 2.2K | ✓ |
| 8 | Epidemiology and Natural History of Inflammatory Bowel Diseases | 2011 | Gastroenterology | 2.1K | ✓ |
| 9 | Crohn's disease | 2012 | The Lancet | 2.1K | ✓ |
| 10 | Quantitative assay for acute intestinal inflammation based on ... | 1984 | Gastroenterology | 1.8K | ✕ |
Frequently Asked Questions
What are neutrophilic dermatoses in autoimmune and inflammatory disorders?
Neutrophilic dermatoses include Pyoderma Gangrenosum and Sweet's Syndrome, often associated with inflammatory bowel diseases. They feature neutrophil infiltration in skin lesions. Assays like neutrophil enzyme markers quantify cutaneous inflammation, as in "Measurement of Cutaneous Inflammation: Estimation of Neutrophil Content with an Enzyme Marker" by Bradley et al. (1982).
How is Crohn's disease activity measured?
A simple index assesses Crohn's disease activity based on symptoms. "A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY" by Harvey and Bradshaw (1980) provides this tool. It enables consistent clinical evaluation.
What treatments work for fistulas in Crohn's disease?
Infliximab induces and maintains fistula response in Crohn's patients. Present et al. (1999) showed efficacy in "Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease". Sands et al. (2004) confirmed sustained benefits with maintenance dosing.
What is the role of vedolizumab in Crohn's disease?
Vedolizumab serves as induction and maintenance therapy for active Crohn's disease. Sandborn et al. (2013) reported higher response rates than placebo in "Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease". It targets gut-specific inflammation.
How is intestinal inflammation quantified?
Myeloperoxidase activity assays measure acute intestinal inflammation. Krawisz et al. (1984) developed this quantitative method in "Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity". It correlates with neutrophil presence.
What defines Wegener granulomatosis outcomes?
Wegener granulomatosis involves vasculitis with improved remission via cyclophosphamide and glucocorticoids in 158 patients. Hoffman et al. (1992) analyzed morbidity in "Wegener Granulomatosis: An Analysis of 158 Patients". Alternative therapies show lower remission rates.
Open Research Questions
- ? How do neutrophil infiltration mechanisms link Pyoderma Gangrenosum, Sweet's Syndrome, and inflammatory bowel diseases at a molecular level?
- ? What optimizes infliximab dosing to minimize loss of response in fistulizing Crohn's disease over extended periods?
- ? Why do some Wegener granulomatosis patients experience profound morbidity despite cyclophosphamide-glucocorticoid remission induction?
- ? How can myeloperoxidase-based assays improve early detection of subclinical intestinal inflammation in neutrophilic dermatoses?
- ? What differentiates histopathology of autoinflammatory skin disorders like histiocytoid Sweet Syndrome from classic presentations?
Recent Trends
The field has 40,692 works with no specified 5-year growth rate; no recent preprints or news coverage from the last 12 months indicate steady focus on established biologics like infliximab and vedolizumab from papers spanning 1980-2013.
Research Autoimmune and Inflammatory Disorders with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Autoimmune and Inflammatory Disorders with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers